646. Subgroup Analyses of Microbiological Cure Rates by Baseline Zoliflodacin MIC and Susceptibility to Ciprofloxacin in Participants from the Global Zoliflodacin Phase 3 Randomized Controlled Trial

Sarah M. McLeod(Innoviva (United States)), Alison Luckey(Global Antibiotic Research & Development Partnership), Khurram Rana(Inova Fairfax Hospital), Esther Bettiol(Global Antibiotic Research & Development Partnership), Varalakshmi Elango(Global Antibiotic Research & Development Partnership), Drew Lewis(Innoviva (United States))
Open Forum Infectious Diseases
January 1, 2026
10.1093/ofid/ofaf695.210
Cited by 1

Related Papers

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
|Hepatology|2015|689
Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study
|Journal of Antimicrobial Chemotherapy|2019|123
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
|The Lancet Infectious Diseases|2024|98
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation
|European Journal of Clinical Pharmacology|2024|28
Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial
|The Lancet|2025|26